Article

The natural L370F ERα Variant Confers Endocrine Resistance and Sensitivity to ATRA in Metastatic Breast Cancer Cells

2025-05-22

Abstract excerpt

<title>Abstract</title> <p>Background. Metastatic breast cancer (MBC) remains a major clinical challenge, particularly in estrogen receptor α (ERα)-positive patients who develop resistance to endocrine therapy (ET). While hotspot mutations such as Y537S in the ligand-binding domain (LBD) are well-characterized drivers of resistance, other ERα variants remain poorly studied. Understanding the molecular mechanisms...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 8cb44b48-a264-5842-b6f4-da597fd55402
DOI: 10.21203/rs.3.rs-6706598/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

The natural L370F ERα Variant Confers Endocrine Resistance and Sensitivity to ATRA in Metastatic Breast Cancer CellsDOI 10.21203/rs.3.rs-6706598/v1Read

The natural L370F ERα variant confers endocrine resistance and sensitivity to ATRA in metastatic breast cancer cells.Semantic proximity Read

Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance.Semantic proximity Read

A Closer Look at Estrogen Receptor Mutations in Breast Cancer and Their Implications for Estrogen and Antiestrogen Responses.Semantic proximity Read

Clinically Observed Estrogen Receptor Alpha Mutations within the Ligand-Binding Domain Confer Distinguishable Phenotypes.Semantic proximity Read

Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models.Semantic proximity Read

Estrogen Receptor Alpha Mutations, Truncations, Heterodimers, and Therapies.Semantic proximity Read

ESR1 mutations and therapeutic resistance in metastatic breast cancer: progress and remaining challenges.Semantic proximity Read

Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer.Semantic proximity Read

Decoding estrogen receptor and GPER biology: structural insights and therapeutic advances in ERα−positive breast cancerSemantic proximity Read

Current Therapeutic Opportunities for Estrogen Receptor Mutant Breast CancerSemantic proximity Read

L370F and Y537S ESR1 mutations determine distinct endocrine therapy sensitivities and metabolic vulnerabilities that define new opportunities for synergistic therapeutic combinationsSemantic proximity Read

Activating ESR1 mutations in hormone-resistant metastatic breast cancer.Semantic proximity Read